Neural repair strategies for Parkinson's disease: insights from primate models

Cell Transplant. 2006;15(3):251-65. doi: 10.3727/000000006783982025.

Abstract

Nonhuman primate models of Parkinson's disease (PD) have been invaluable to our understanding of the human disease and in the advancement of novel therapies for its treatment. In this review, we attempt to give a brief overview of the animal models of PD currently used, with a more comprehensive focus on the advantages and disadvantages presented by their use in the nonhuman primate. In particular, discussion addresses the 6-hydroxydopamine (6-OHDA), 1-methyl-1,2,3,6-tetrahydopyridine (MPTP), rotenone, paraquat, and maneb parkinsonian models. Additionally, the role of primate PD models in the development of novel therapies, such as trophic factor delivery, grafting, and deep brain stimulation, are described. Finally, the contribution of primate PD models to our understanding of the etiology and pathology of human PD is discussed.

Publication types

  • Review

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / adverse effects
  • Animals
  • Cell Transplantation
  • Deep Brain Stimulation
  • Disease Models, Animal*
  • Fungicides, Industrial / adverse effects
  • Glial Cell Line-Derived Neurotrophic Factor / therapeutic use
  • Herbicides / adverse effects
  • Humans
  • Maneb / adverse effects
  • Nerve Degeneration / chemically induced
  • Nerve Degeneration / pathology*
  • Nerve Degeneration / therapy*
  • Oxidopamine / adverse effects
  • Paraquat / adverse effects
  • Parkinson Disease / etiology
  • Parkinson Disease / pathology*
  • Parkinson Disease / therapy*
  • Pesticides / adverse effects
  • Primates
  • Rotenone / adverse effects

Substances

  • Fungicides, Industrial
  • Glial Cell Line-Derived Neurotrophic Factor
  • Herbicides
  • Pesticides
  • Rotenone
  • Maneb
  • Oxidopamine
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Paraquat